Ocular Therapeutix
OCUL
113 hedge funds and large institutions have $127M invested in Ocular Therapeutix in 2023 Q3 according to their latest regulatory filings, with 8 funds opening new positions, 45 increasing their positions, 29 reducing their positions, and 29 closing their positions.
199% more call options, than puts
Call options by funds: $1.04M | Put options by funds: $350K
55% more repeat investments, than reductions
Existing positions increased: 45 | Existing positions reduced: 29
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
5.15% less ownership
Funds ownership: 56.05% → 50.91% (-5.1%)
16% less funds holding
Funds holding: 134 → 113 (-21)
43% less capital invested
Capital invested by funds: $224M → $127M (-$97.2M)
72% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 29
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OM
Opaleye Management
Boston,
Massachusetts
|
+$2.82M |
| 2 |
PAMP
Polar Asset Management Partners
Toronto,
Ontario, Canada
|
+$1.08M |
| 3 |
State Street
Boston,
Massachusetts
|
+$842K |
| 4 |
SAM
Sectoral Asset Management
Montreal,
Quebec, Canada
|
+$682K |
| 5 |
Axa
Paris,
France
|
+$672K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$7M |
| 2 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$3.33M |
| 3 |
EIM
Essex Investment Management
Boston,
Massachusetts
|
-$1.55M |
| 4 |
LCM
Lynwood Capital Management
Toronto,
Ontario, Canada
|
-$1.35M |
| 5 |
Two Sigma Advisers
New York
|
-$1.31M |
OCUL Hedge Fund Activity: Q3 2023 in Review
113 of the 6,310 institutional investors tracked by Wall St. Rank reported a position in Ocular Therapeutix (OCUL) for Q3 2023, worth a combined $127M — down 43% from $224M a quarter earlier.
Sellers outnumbered buyers: 29 funds closed out of OCUL and 8 opened new positions — a net loss of 21 holders — while 29 trimmed existing stakes and 45 added.
The largest buyer was Opaleye Management, adding an estimated $2.82M. The largest seller was Millennium Management, cutting an estimated $7M.
- 113 institutional investors held Ocular Therapeutix (OCUL) as of Q3 2023, down from 134 in Q2 2023.
- Funds reported $127M of Ocular Therapeutix stock for Q3 2023, down 43% quarter-over-quarter.
- 8 funds opened new Ocular Therapeutix positions in Q3 2023 and 29 closed out, a net change of -21 holders.
- The largest Ocular Therapeutix buyer in Q3 2023 was Opaleye Management, an estimated $2.82M added.
- The largest Ocular Therapeutix seller in Q3 2023 was Millennium Management, an estimated $7M sold.
Based on aggregated 13F filings for Q3 2023.